MA50798A - Procédés d'utilisation et compositions contenant du dulaglutide - Google Patents

Procédés d'utilisation et compositions contenant du dulaglutide

Info

Publication number: MA50798A
Authority: MA; Morocco
Prior art keywords: methods; compositions containing; dulaglutide; containing dulaglutide; compositions
Prior art date: 2017-11-21

Application number

MA050798A

Other languages

English (en)

Inventor

David Andrew Cox

Zvonko Milicevic

Lai San Tham

Andrew Gordon Werner

David Bradley Woodward

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-11-21

Filing date

2018-11-13

Publication date

2020-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50798(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-11-13 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2020-09-30 Publication of MA50798A publication Critical patent/MA50798A/fr

Links

229960005175 dulaglutide Drugs 0.000 title 1
108010005794 dulaglutide Proteins 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Obesity (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Plant Substances (AREA)

MA050798A 2017-11-21 2018-11-13 Procédés d'utilisation et compositions contenant du dulaglutide MA50798A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762589244P	2017-11-21	2017-11-21

Publications (1)

Publication Number	Publication Date
MA50798A true MA50798A (fr)	2020-09-30

Family

ID=64572530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050798A MA50798A (fr)	2017-11-21	2018-11-13	Procédés d'utilisation et compositions contenant du dulaglutide

Country Status (21)

Country	Link
US (2)	US11576950B2 (fr)
EP (1)	EP3713593A2 (fr)
JP (3)	JP7221956B2 (fr)
KR (2)	KR102589234B1 (fr)
CN (2)	CN111356472A (fr)
AU (2)	AU2018372709B2 (fr)
BR (1)	BR112020007817A2 (fr)
CL (1)	CL2020001252A1 (fr)
CR (1)	CR20200202A (fr)
DO (1)	DOP2020000104A (fr)
EA (1)	EA202090971A1 (fr)
EC (1)	ECSP20026436A (fr)
IL (1)	IL274563B2 (fr)
JO (1)	JOP20200126B1 (fr)
MA (1)	MA50798A (fr)
MX (1)	MX2020005231A (fr)
PE (1)	PE20200847A1 (fr)
PH (1)	PH12020550795A1 (fr)
SG (1)	SG11202003687RA (fr)
UA (1)	UA127588C2 (fr)
WO (1)	WO2019103875A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN113613629A (zh) *	2019-03-15	2021-11-05	伊莱利利公司	防腐的制剂
US20230088005A1 (en) *	2020-01-30	2023-03-23	Eli Lilly And Company	Therapeutic uses of dulaglutide
JP2023525898A (ja) *	2020-05-19	2023-06-19	エフ．ホフマン－ラロシュアーゲー	非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
AU2022298662B2 (en)	2021-06-23	2025-06-05	Eli Lilly And Company	An incretin analog for use in glycemic control and weight management

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1724284T1 (sl)	2000-12-07	2009-12-31	Lilly Co Eli	Glp-1 fuzijski proteini
ES2371072T3 (es)	2003-06-12	2011-12-27	Eli Lilly And Company	Proteínas de fusión análogas de glp-1.
JP2008525452A (ja)	2004-12-22	2008-07-17	イーライリリーアンドカンパニー	Ｇｌｐ−１類似体融合蛋白質製剤
KR20100020516A (ko) *	2007-07-10	2010-02-22	일라이 릴리 앤드 캄파니	Ｇｌｐ-1-ｆｃ 융합 단백질 제제
AR100639A1 (es) *	2014-05-29	2016-10-19	Hanmi Pharm Ind Co Ltd	Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (fr) *	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Thérapies pour l'obésité, le diabète et indications associées
US20200171129A1 (en)	2017-06-01	2020-06-04	Eli Lilly And Company	Therapeutic uses of dulaglutide

2018
- 2018-11-13 MA MA050798A patent/MA50798A/fr unknown
- 2018-11-13 PH PH1/2020/550795A patent/PH12020550795A1/en unknown
- 2018-11-13 CR CR20200202A patent/CR20200202A/es unknown
- 2018-11-13 UA UAA202002355A patent/UA127588C2/uk unknown
- 2018-11-13 EP EP18812499.4A patent/EP3713593A2/fr active Pending
- 2018-11-13 AU AU2018372709A patent/AU2018372709B2/en active Active
- 2018-11-13 MX MX2020005231A patent/MX2020005231A/es unknown
- 2018-11-13 CN CN201880075369.5A patent/CN111356472A/zh active Pending
- 2018-11-13 CN CN202510640885.XA patent/CN120478602A/zh active Pending
- 2018-11-13 SG SG11202003687RA patent/SG11202003687RA/en unknown
- 2018-11-13 IL IL274563A patent/IL274563B2/en unknown
- 2018-11-13 PE PE2020000547A patent/PE20200847A1/es unknown
- 2018-11-13 JP JP2020525974A patent/JP7221956B2/ja active Active
- 2018-11-13 KR KR1020207014456A patent/KR102589234B1/ko active Active
- 2018-11-13 KR KR1020227035115A patent/KR20220146656A/ko not_active Ceased
- 2018-11-13 BR BR112020007817-4A patent/BR112020007817A2/pt not_active Application Discontinuation
- 2018-11-13 US US16/763,269 patent/US11576950B2/en active Active
- 2018-11-13 WO PCT/US2018/060716 patent/WO2019103875A2/fr not_active Ceased
- 2018-11-13 EA EA202090971A patent/EA202090971A1/ru unknown
2020
- 2020-05-12 CL CL2020001252A patent/CL2020001252A1/es unknown
- 2020-05-20 EC ECSENADI202026436A patent/ECSP20026436A/es unknown
- 2020-05-21 JO JOJO/P/2020/0126A patent/JOP20200126B1/ar active
- 2020-06-01 DO DO2020000104A patent/DOP2020000104A/es unknown
2022
- 2022-02-01 JP JP2022014339A patent/JP7818412B2/ja active Active
- 2022-05-18 AU AU2022203372A patent/AU2022203372B2/en active Active
2023
- 2023-01-04 US US18/149,982 patent/US20240189394A1/en active Pending
2024
- 2024-02-16 JP JP2024021637A patent/JP2024056908A/ja active Pending

Also Published As

Publication number	Publication date
JP7221956B2 (ja)	2023-02-14
DOP2020000104A (es)	2020-08-31
UA127588C2 (uk)	2023-10-25
BR112020007817A2 (pt)	2020-10-06
WO2019103875A3 (fr)	2019-07-25
KR102589234B1 (ko)	2023-10-16
EP3713593A2 (fr)	2020-09-30
CN111356472A (zh)	2020-06-30
AU2018372709A1 (en)	2020-05-14
SG11202003687RA (en)	2020-06-29
US11576950B2 (en)	2023-02-14
KR20200076705A (ko)	2020-06-29
JP2024056908A (ja)	2024-04-23
WO2019103875A2 (fr)	2019-05-31
PE20200847A1 (es)	2020-08-18
MX2020005231A (es)	2020-08-24
US20240189394A1 (en)	2024-06-13
ECSP20026436A (es)	2020-06-30
PH12020550795A1 (en)	2021-04-19
JOP20200126A1 (ar)	2020-05-21
JOP20200126B1 (ar)	2024-04-18
AU2022203372A1 (en)	2022-06-09
CL2020001252A1 (es)	2020-10-30
JP7818412B2 (ja)	2026-02-20
AU2022203372B2 (en)	2025-04-10
IL274563A (en)	2020-06-30
AU2018372709B2 (en)	2022-04-28
US20200330558A1 (en)	2020-10-22
JP2022062153A (ja)	2022-04-19
CR20200202A (es)	2020-08-20
CN120478602A (zh)	2025-08-15
CA3082625A1 (fr)	2019-05-31
EA202090971A1 (ru)	2020-08-07
IL274563B2 (en)	2023-12-01
KR20220146656A (ko)	2022-11-01
NZ763815A (en)	2023-11-24
JP2021502379A (ja)	2021-01-28
IL274563B1 (en)	2023-08-01

Publication	Publication Date	Title
EP3704239A4 (fr)	2021-08-18	Compositions de casz et procédés d'utilisation
EP3277698A4 (fr)	2019-03-20	Composition filmogène contenant du si et ses procédés d'utilisation
EP3634430A4 (fr)	2021-04-14	Agents multibiotiques et procédés d'utilisation de ceux-ci
EP3790596A4 (fr)	2022-04-06	Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3890736A4 (fr)	2022-08-10	Agents de dégradations de petites molécules de helios et procédés d'utilisation
EP3703806A4 (fr)	2021-05-26	Dispositifs d'hémostase et procédés d'utilisation
EP3775203A4 (fr)	2022-03-30	Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630199A4 (fr)	2021-11-10	Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630788A4 (fr)	2021-04-28	Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630789A4 (fr)	2021-06-16	Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3612198A4 (fr)	2021-01-13	Bactéries commensales modifiées et procédés d'utilisation
EP3402493A4 (fr)	2019-08-21	Composition d'organoïde neural et procédés d'utilisation
EP3893917A4 (fr)	2023-01-11	Compositions d'il-15 et leurs procédés d'utilisation
EP3435956A4 (fr)	2020-01-15	Compositions photo-stabilisées et leurs procédés d'utilisation
EP3452597A4 (fr)	2020-05-06	Procédés et compositions d'agents biologiquement actifs
EP3303634A4 (fr)	2019-03-20	Variants de cas9 et procédés d'utilisation associés
EP3487379A4 (fr)	2020-04-01	Dispositifs médicaux et procédés d'utilisation
EP3635000A4 (fr)	2021-04-14	Manabodies et procédés d'utilisation
EP3313404A4 (fr)	2019-08-07	Compositions thérapeutiques, associations et procédés d'utilisation
EP3352774A4 (fr)	2019-04-03	Compositions de flavonoïdes et procédés d'utilisation
EP3414321A4 (fr)	2019-07-10	Compositions améliorant vcn et procédés d'utilisation desdites compositions
EP3490569A4 (fr)	2020-04-15	Compositions topiques et ses procédés d'utilisation
MA48797A (fr)	2020-04-08	Variants de l'endonucléase cblb , compositions et procédés d'utilisation
EP3525855A4 (fr)	2020-06-17	Inhalateur et procédés d'utilisation associés
EP3666729A4 (fr)	2020-06-17	Composition contenant du nano-soufre et application associée